ALNYLAM PHARMACEUTICALS, INC.

Alnylam Pharmaceuticals, Inc.

Biotechnology • Healthcare • Cambridge, MA, United States • ALNY (NMS)

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

617 551 8200 675 West Kendall Street, Cambridge, MA 02142, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options - Yahoo Finance
Yahoo Finance • Dec 12
Alnylam Pharmaceuticals: Challenges In The TTR Space And Few Late-Stage Catalysts Are A Concern - Seeking Alpha
Seeking Alpha • Dec 13
Is Alnylam Pharmaceuticals a Millionaire Maker? - The Motley Fool
The Motley Fool • Dec 7
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Cwm LLC - MarketBeat
MarketBeat • Dec 29
Here’s why Alnylam Pharmaceuticals (ALNY) surged in Q3 - MSN
MSN • Dec 19

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap
BeOne Medicines Ltd. logo Beone Medicines Ltd.
$36.39B market cap

Frequently Asked Questions

Has ALNYLAM PHARMACEUTICALS, INC. had layoffs?
No layoff events have been recorded for ALNYLAM PHARMACEUTICALS, INC. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does ALNYLAM PHARMACEUTICALS, INC. have?
ALNYLAM PHARMACEUTICALS, INC. has approximately 2,230 employees.
What industry is ALNYLAM PHARMACEUTICALS, INC. in?
ALNYLAM PHARMACEUTICALS, INC. operates in the Biotechnology industry, within the Healthcare sector.
Is ALNYLAM PHARMACEUTICALS, INC. a publicly traded company?
Yes, ALNYLAM PHARMACEUTICALS, INC. is publicly traded under the ticker symbol ALNY on the NMS. The company has a market capitalization of approximately $52.92 billion.
Where is ALNYLAM PHARMACEUTICALS, INC. headquartered?
ALNYLAM PHARMACEUTICALS, INC. is headquartered in Cambridge, MA, United States at 675 West Kendall Street, Cambridge, MA 02142, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.